Considerations for developing an immunization strategy with enterovirus 71 vaccine

Vaccine

Volumn 33, Issue 9, 2015, Pages 1107-1112

  Li, Li ^a   Yin, Hongzhang ^b   An, Zhijie ^a   Feng, Zijian ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Key lab of biological evaluation of medical devices of Shandong province   (China)

Author keywords

Enterovirus 71; Hand, foot, and mouth disease; Immunization strategy; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; ENTEROVIRUS 71 VACCINE; HEPATITIS B VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE;

CHINA; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG USE; ENTEROVIRUS 71; EPIDEMIC; EPIDEMIOLOGICAL DATA; FORECASTING; GROUPS BY AGE; HAND FOOT AND MOUTH DISEASE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MORBIDITY; MORTALITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SEROEPIDEMIOLOGY; VIRUS IMMUNITY; VIRUS TRANSMISSION; ENTEROVIRUS A; HAND, FOOT AND MOUTH DISEASE; IMMUNOLOGY; PROCEDURES;

CHINA; CLINICAL TRIALS AS TOPIC; ENTEROVIRUS A, HUMAN; HAND, FOOT AND MOUTH DISEASE; HUMANS; IMMUNIZATION; VIRAL VACCINES;

EID: 84922861086     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.081     Document Type: Review

References (35)

1. Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010, 10:778-790.
2. World Health Organization Western Pacific Region A guide to clinical management and public health response for hand, foot and mouth disease (HFMD) 2011, World Health Organization Western Pacific Region, Manila.
3. Ooi E.E., Phoon M.C., Ishak B., Chan S.H. Seroepidemiology of human enterovirus 71, Singapore. Emerg Infect Dis 2002, 8:995-997.
4. Chang L.Y., King C.C., Hsu K.H., Ning H.C., Tsao K.C., Li C.C., et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 2002, 109:e88.
5. Xing W., Liao Q., Viboud C., Zhang J., Sun J., Wu J.T., et al. Hand, foot, and mouth disease in China, 2008-2012: an epidemiological study. Lancet Infect Dis 2014, 14:308-318.
6. Zhang Y., Tan X.J., Wang H.Y., Yan D.M., Zhu S.L., Wang D.Y., et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 2009, 44:262-267.
7. Zhang Y., Zhu Z., Yang W., Ren J., Tan X., Wang Y., et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J 2010, 7:94.
8. De W., Changwen K., Wei L., Monagin C., Jin Y., Cong M., et al. A large outbreak of hand, foot, and mouth disease caused by EV71 and CVA16 in Guangdong, China, 2009. Arch Virol 2011, 156:945-953.
9. Li W., Yi L., Su J., Lu J., Ke C., Zeng H., et al. Seroprevalence of human enterovirus 71 and coxsackievirus A16 in Guangdong, China, in pre- and post-2010 HFMD epidemic period. PLoS One 2013, 8:e80515.
10. Chua K.B., Chua B.H., Lee C.S., Chem Y.K., Ismail N., Kiyu A., et al. Genetic diversity of enterovirus 71 isolated from cases of hand, foot and mouth disease in the 1997, 2000 and 2005 outbreaks, Peninsular Malaysia. Malays J Pathol 2007, 29:69-78.
11. Chua K.B., Kasri A.R. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin 2011, 26:221-228.
12. Khanh T.H., Sabanathan S., Thanh T.T., Thoa L.P.K., Thuong T.C., Hang V.T., et al. Enterovirus 71-associated hand, foot, and mouth disease, southern Vietnam, 2011. Emerg Infect Dis 2012, 18:2002-2005.
13. Ang L.W., Koh B.K., Chan K.P., Chua L.T., James L., Goh K.T. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad Med Singapore 2009, 38:106-112.
14. Wu Y., Yeo A., Phoon M.C., Tan E.L., Poh C.L., Quak S.H., et al. The largest outbreak of hand foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010, 14:e1076-e1081.
15. Linsuwanon P., Puenpa J., Huang S.W., Wang Y.F., Mauleekoonphairoj J., Wang J.R., et al. Epidemiology and seroepidemiology of human enterovirus 71 among Thai populations. J Biomed Sci 2014, 21:16.
16. Ma E., Lam T., Chan K.C., Wong C., Chuang S.K. Changing epidemiology of hand, foot, and mouth disease in Hong Kong, 2001-2009. Jpn J Infect Dis 2010, 63:422-426.
17. Chen K.T., Chang H.L., Wang S.T., Cheng Y.T., Yang J.Y. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005. Pediatrics 2007, 120:e244-e252.
18. Wu W.H., Kuo T.C., Lin Y.T., Huang S.W., Liu H.F., Wang J., et al. Molecular epidemiology of enterovirus 71 infection in the central region of Taiwan from 2002 to 2012. PLoS One 2013, 8:e83711.
19. Meng F.Y., Li J.X., Li X.L., Chu K., Zhang Y.T., Ji H., et al. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccin Immunother 2012, 8:668-674.
20. Ma E., Chan K.C., Cheng P., Wong C., Chuang S.K. The enterovirus 71 epidemic in 2008-public health implications for Hong Kong. Int J Infect Dis 2010, 14:e775-e780.
21. Zhu F.C., Liang Z.L., Meng F.Y., Zeng Y., Mao Q.Y., Chu K., et al. Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants. PLoS One 2012, 7:e37206.
22. Ma E., Fung C., Yip S.H.L., Wong C., Chuang S.K., Tsang T. Estimation of the basic reproduction number of enterovirus 71 and coxsackievirus A16 in hand, foot, and mouth disease outbreaks. Pediatr Infect Dis J 2011, 30:675-679.
23. Yang T.C., Yi B., He T.F., Wu Y.P., Ma Y., Xu G.F., et al. Economic burden of hand, foot and mouth disease in Ningbo, Zhejiang. Dis Surveill 2012, 27:520-523. (in Chinese).
24. Zhu F.C., Wang J.Z., Li X.L., Liang Z.L., Ge H.M., Meng F.Y., et al. Reactogenicity and immunogenicity of an enterovirus 71 vaccine in Chinese healthy children and infants. Pediatr Infect Dis J 2012, 31:1158-1165.
25. Chen Y.J., Meng F.Y., Mao Q.Y., Li J.X., Wang H., Liang Z.L., et al. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial. Hum Vaccin Immunother 2014, 10:1366-1372.
26. Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013, 381:2024-2032.
27. Li Y.P., Liang Z.L., Gao Q., Huang L.R., Mao Q.Y., Wen S.Q., et al. Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial. Vaccine 2012, 30:3295-3303.
28. Li Y.P., Liang Z.L., Xia J.L., Wu J.Y., Wang L., Song L.F., et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, randomized, doubleblind, placebo-controlled trial. J Infect Dis 2014, 209:46-55.
29. Hu Y.M., Wang X., Wang J.Z., Wang L., Zhang Y.J., Chang L., et al. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol 2013, 20:1805-1811.
30. Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014, 370:818-828.
31. Liu L., Zhang Y., Wang J., Zhao H., Jiang L., Che Y., et al. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One 2013, 8:e54451.
32. Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014, 370:829-837.
33. Chou A.H., Liu C.C., Chang J.Y., Jiang R., Hsieh Y.C., Tsao A., et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One 2013, 8:e79788.
34. Mao Q., Cheng T., Zhu F., Li J., Yang Y., Li Y., et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy Chinese infants and children. PLoS One 2013, 8:e79599.
35. Lee BY1, Wateska A.R., Bailey R.R., Tai J.H.Y., Bacon K.M., Smith K.J. Forecasting the economic value of an enterovirus 71 (EV71) vaccine. Vaccine 2010, 28:7731-7736.